权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigating the Gut Microbiome for Novel Therapies and Diagnostics for Autism

研究肠道微生物组以寻找自闭症的新疗法和诊断

基本信息

批准号：
9266505
负责人：
Sarkis K Mazmanian
金额：
$ 55.81万
依托单位：
CALIFORNIA INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-15 至 2019-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9266505
关键词：
Adult Affect Age Animals Appearance Area Autistic Disorder Bacteria Bacterial Translocation Bacteroides fragilis Behavior Behavior Disorders Behavioral Behavioral Symptoms Biological Assay Biological Markers Blood Circulation Brain Centers for Disease Control and Prevention (U.S.)Child Colon Communication Complex Data Defect Development Diagnosis Diagnostic Disease Early Diagnosis Employee Strikes Environmental Risk Factor Epithelial Etiology Exhibits Functional disorder Genetic Risk Goals Human Immune Immune Sera Immune system Interleukin-6 Intervention Intestines Language Lead Lifestyle-related condition Mediating Medical Microglia Modeling Molecular Molecular Profiling Mus Neurodevelopmental Disability Pathology Patients Peripheral Permeability Pre-Clinical Model Probiotics Process Proteins Reporting Research Risk Factors Serum Serum Immunologic Social Interaction Stereotyped Behavior Symptoms Testing Therapeutic Tight Junctions Time United States Up-Regulation autism spectrum disorder autistic children base commensal microbes cytokine effective therapy experimental study feeding gastrointestinal gastrointestinal bacteria gastrointestinal symptom gut microbiome gut microbiota immune activation innovation interest intestinal epithelium maternal serum metabolomics microbiota mouse model neuropathology novel novel diagnostics novel therapeutics offspring patient subsets potential biomarker prevent probiotic therapy relating to nervous system repetitive behavior sex social

项目摘要

Autism spectrum disorder (ASD) comprises a set of complex neurodevelopmental disabilities characterized by repetitive/stereotypic behaviors and deficits in communication and social interaction. Recent studies highlight striking neural and peripheral immune dysregulation in ASD. Moreover, a significant subset of ASD children exhibit gastrointestinal (GI) complications, including increased intestinal permeability and altered composition of intestinal microbiota. The potential connections between GI abnormalities, intestinal bacteria, and behavioral deficits have not yet been convincingly investigated. To examine the hypothesis that GI pathology is associated with, and contributes to behavioral symptoms, we employ a mouse model of an ASD risk factor, maternal immune activation (MIA). Our results show that these mice, which display cardinal ASD-like behaviors and neuropathology, also exhibit GI pathology. This includes changes in expression of tight junction components in the intestinal epithelium and a �leaky gut�, or diminished epithelial barrier function, which is reported in a significant subset of ASD children. Remarkably, this leaky gut is associated with an altered metabolite profile in the serum of the MIA mice, suggesting that GI permeability results in translocation of bacterial products into the circulation. Furthermore, we show that administration of a probiotic bacterium, Bacteroides fragilis, to these mice cures several behavioral abnormalities while restoring GI barrier function. Our central hypothesis is that correcting GI abnormalities with probiotic bacteria may be a safe and effective treatment for some of the abnormal behaviors in ASD. The specific aims that will test this hypothesis are: 1) in mechanistic experiments, determine if a cytokine relevant to MIA induces leaky gut and 2) determine whether putative metabolites that leak from the gut contribute to or modify behavioral abnormalities. Based on compelling preliminary evidence, this project aims to explore the potential connection between GI barrier defects and altered behavior in preclinical models of autism. Our long-term goal is to explore possible serum biomarkers for ASD diagnosis, and potentially develop a novel probiotic therapy for at least a subset of children with ASD with GI issues.

自闭症谱系障碍（ASD）包括一组复杂的神经发育障碍，其特征在于重复/刻板行为以及沟通和社会互动的缺陷。最近的研究强调了ASD中显著的神经和外周免疫失调。此外，ASD儿童的一个重要子集表现出胃肠道（GI）并发症，包括肠道通透性增加和肠道微生物群组成改变。胃肠道异常、肠道细菌和行为缺陷之间的潜在联系尚未得到令人信服的研究。为了检验GI病理与行为症状相关并促成行为症状的假设，我们采用ASD风险因素-母体免疫激活（MIA）-的小鼠模型。我们的研究结果表明，这些小鼠，这显示了基本的ASD样行为和神经病理学，也表现出胃肠道病理学。这包括肠上皮中紧密连接成分表达的变化和“漏肠”，或上皮屏障功能减弱，这在ASD儿童的重要子集中有报道。值得注意的是，这种漏肠与MIA小鼠血清中代谢物谱的改变有关，表明GI渗透性导致细菌产物易位进入循环。此外，我们表明，管理的益生菌，脆弱拟杆菌，这些小鼠治愈几个行为异常，同时恢复胃肠道屏障功能。我们的中心假设是，用益生菌纠正GI异常可能是ASD中某些异常行为的安全有效的治疗方法。检验这一假设的具体目的是：1）在机理实验中，确定与MIA相关的细胞因子是否诱导肠漏，2）确定从肠漏的推定代谢物是否有助于或改变行为异常。基于令人信服的初步证据，该项目旨在探索自闭症临床前模型中GI屏障缺陷和行为改变之间的潜在联系。我们的长期目标是探索ASD诊断的可能血清生物标志物，并可能为至少一部分患有ASD的GI问题儿童开发新型益生菌疗法。